Related Experiment Video
Updated: Mar 3, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
Shu-Fu Lin1, Jen-Der Lin1, Chuen Hsueh2
1Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Abstract:
Heat shock protein 90 is a molecular chaperon that maintains the correct folding and function of multiple client proteins. The inhibition of heat shock protein 90, which leads to the simultaneous degradation of multiple proteins involved in oncogenic signaling pathways, has revealed an innovative strategy to treat a variety of cancer types. We evaluated the therapeutic effects of ganetespib, a heat shock protein 90 inhibitor, in treating thyroid cancer. Ganetespib effectively inhibited cell proliferation in a dose-dependent manner in eight cell lines originating from four major histologic types of thyroid cancer (papillary, follicular, anaplastic and medullary). Ganetespib decreased cyclin-dependent kinase 1 and arrested cell cycle progression in G2/M phase. The expression of proteins involved in RAS/RAF/ERK and PI3K/AKT/mTOR signaling pathways was also inhibited. The RET level was decreased in a medullary thyroid cancer cell line. Ganetespib increased Bim expression, activated caspase-3 and induced apoptosis. In vivo, ganetespib retarded the tumor growth of anaplastic and medullary thyroid cancer xenografts with acceptable safety profiles. These findings indicate that ganetespib has potential in the treatment of patients with thyroid cancer.
Insights
Ganetespib, a heat shock protein 90 inhibitor, effectively reduced thyroid cancer cell proliferation and tumor growth in preclinical models. This suggests ganetespib holds promise for treating various thyroid cancer types.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Heat shock protein 90 (HSP90) is crucial for maintaining oncogenic protein function.
- HSP90 inhibition offers a therapeutic strategy by degrading multiple oncoproteins simultaneously.
- Thyroid cancer treatment options remain limited, particularly for advanced stages.
Purpose of the Study:
- To evaluate the therapeutic potential of ganetespib, an HSP90 inhibitor, in thyroid cancer.
- To investigate ganetespib's effects on thyroid cancer cell proliferation, cell cycle, and signaling pathways.
- To assess ganetespib's efficacy and safety in preclinical thyroid cancer models.
Main Methods:
- In vitro studies using eight thyroid cancer cell lines (papillary, follicular, anaplastic, medullary).
- Assessment of cell proliferation, cell cycle progression (G2/M arrest), and apoptosis induction (caspase-3 activation, Bim expression).
- In vivo studies using anaplastic and medullary thyroid cancer xenografts.
Main Results:
- Ganetespib inhibited thyroid cancer cell proliferation and induced G2/M cell cycle arrest.
- Ganetespib suppressed key oncogenic signaling pathways (RAS/RAF/ERK, PI3K/AKT/mTOR) and RET expression.
- Ganetespib demonstrated significant tumor growth retardation in vivo with a favorable safety profile.
Conclusions:
- Ganetespib exhibits potent anti-cancer activity against diverse thyroid cancer subtypes.
- Ganetespib effectively targets multiple oncogenic pathways crucial for thyroid cancer progression.
- Ganetespib represents a promising therapeutic candidate for thyroid cancer treatment.
